Company intelligence / Profile preview

CoV Biotechnology

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

CoV Biotechnology developed vaccine and monoclonal antibody assets targeting a broad spectrum of beta-coronaviruses. Its lead programs included a pan-sarbecovirus vaccine candidate and monoclonal antibodies with cross-protective potential. The company was acquired by Leyden Labs in early 2025, becoming its Asian subsidiary, with ongoing development of these assets under the new brand[1][4].

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccinesmRNA vaccinesMonoclonal antibodies[1][2][4]
Industry: Biotech

Drug pipeline

1 asset

Pan-sarbecovirus vaccine

Pre-clinical

Indications: COVID-19, Coronavirus infections

Partnerships

Multiple potential partners discussed post-acquisition regarding avian flu preparedness; specifics not disclosed yet[4].

Beyond the preview

Go deeper on CoV Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoV Biotechnology.

Explore the full profile